« Back
Home /
Iniparib

Iniparib

Manufacturer	ChemScene
Category	Reagents & Chemicals Molecules
Type	Molecules
Specific against	other
Amount	200mg
Item no.	CS-0145-200mg
eClass 6.1	32169090
eClass 9.0	32169090
Available
Alternative Names	BSI-201; NSC-746045; IND-71677
CAS	160003-66-7
Purity	>98%
Formula	C7H5IN2O3
MWt	292.03
Solubility	DMSO : 100 mg/mL (342.43 mM; Need ultrasonic)
Clinical Information	Phase 3
Pathway	Epigenetics; Cell Cycle/DNA Damage
Target	PARP; PARP
Biological Activity	Iniparib (BSI-201) is an irreversible inhibitor of PARP1, used in the research of triple negative breast cancer. IC50 & Target: PARP1^[3] In Vitro: Iniparib nonselectively modifies cysteine-containing proteins in tumor cells^[1]. Iniparib (100 uM) weakly inhibits SSB repair, and the inhibition can be reversed by knockdown of PARP1^[2]. Iniparib in combination with cisplatin is cytotoxic to Myc/MDA-231 with EMT changes^[3].

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

CS-0145-200mg-datasheet.pdf

Request safety datasheet

Simple Order Order Subscription

Amount: 200mg

available

Delivery expected until 6/6/2024